DSM and Crucell sign PER.C6(R) licence agreements

Published: 19-Dec-2008

DSM Biologics, a division of DSM Pharmaceutical Products, and Dutch biotechnology company Crucell have signed commercial licence agreements with Hungary-based Gedeon Richter and GSK, which will allow both companies to develop biopharmaceuticals on the PER.C6(R) platform.


DSM Biologics, a division of DSM Pharmaceutical Products, and Dutch biotechnology company Crucell have signed commercial licence agreements with Hungary-based Gedeon Richter and GSK, which will allow both companies to develop biopharmaceuticals on the PER.C6(R) platform.

Financial terms were not disclosed.

Crucell's PER.C6(R) technology platform has been developed for the large-scale manufacture of biopharmaceutical products such as recombinant proteins including monoclonal antibodies. The company says the strengths of PER.C6(R) lie in its excellent safety profile, scalability and productivity under serum-free culture conditions.

Gedeon Richter will develop and produce "certain biopharmaceuticals" on the PER.C6(R) platform, while GSK will research a recombinant protein.

Karen King, president of DSM Biologics, said: "The PER.C6(R) production technology continues to surpass our expectations as a robust manufacturing platform with its ever extending and global reach into the r&d departments of major healthcare players."

You may also like